Rabbit PARK2 Polyclonal Antibody | anti-PARK2 antibody

PARK2 (Parkin, AR-JP, LPRS2, PDJ, PRKN) (HRP)

Cat. Num. AAA6430559

• Gene Names: PARK2; PDJ; PRKN; AR-JP; LPRS2
• Reactivity: Human, Mouse, Rat
• Applications: Immunofluorescence, Western Blot, Immunohistochemistry
• Purity: Purified by affinity chromatography.
• Synonyms: PARK2; Polyclonal Antibody; PARK2 (Parkin; AR-JP; LPRS2; PDJ; PRKN) (HRP); anti-PARK2 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes PARK2. Species Crossreactivity: human, mouse, rat
• Purity/Purification: Purified by affinity chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Horseradish Peroxidase (HRP).
• Concentration: ~1mg/ml (varies by lot)

• Applicable Applications for anti-PARK2 antibody: Immunofluorescence (IF), Western Blot (WB), Immunohistochemistry (IHC)
• Application Notes: IF: 1:50-1:200; WB: 1:500-1:2000; IHC: 1:50-1:200; Applications are based on unconjugated antibody.
• Immunogen: Recombinant protein corresponding to human PARK2.
• Conjugate: HRP
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20 degree C. Aliquots are stable at -20 degree C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB)

(Western blot analysis of various cell lines, using PARK2 antibody.)

Immunohistochemistry (IHC)

(Immunohistochemistry of paraffin-embedded mouse heart using PARK2 antibody at dilution of 1:200 (200x lens).)

Immunofluorescence (IF)

(Immunofluorescence analysis of HeLa cell using PARK2 antibody. Blue: DAPI for nuclear staining.)

Product Categories/Family for anti-PARK2 antibody

Antibodies; Ubiquitin Ligases

NCBI and Uniprot Product Information

• NCBI GI #: 169790969
• NCBI GeneID: 5071
• NCBI Accession #: NP_004553.2
• NCBI GenBank Nucleotide #: NM_004562.2
• UniProt Accession #: O60260; Q5TFV8; Q6Q2I6; Q8NI41; Q8NI43; Q8NI44; Q8WW07; A3FG77; A8K975
• Molecular Weight: 51,641 Da
• NCBI Official Full Name: E3 ubiquitin-protein ligase parkin isoform 1
• NCBI Official Synonym Full Names: parkinson protein 2, E3 ubiquitin protein ligase (parkin)
• NCBI Official Symbol: PARK2
• NCBI Official Synonym Symbols: PDJ; PRKN; AR-JP; LPRS2
• NCBI Protein Information: E3 ubiquitin-protein ligase parkin; parkinson juvenile disease protein 2; Parkinson disease (autosomal recessive, juvenile) 2, parkin
• UniProt Protein Name: E3 ubiquitin-protein ligase parkin
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: PARK2
• UniProt Synonym Gene Names: PRKN; Parkinson disease protein 2
• UniProt Entry Name: PRKN2_HUMAN

NCBI Description

The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008]

Uniprot Description

PARK2: a component of a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene. Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING- type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1. Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum. Belongs to the RBR family. Parkin subfamily. 6 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 6.3.2.19; Ubiquitin conjugating system; Ubiquitin ligase; EC 6.3.2.-; Ligase

Chromosomal Location of Human Ortholog: 6q25.2-q27

Cellular Component: Golgi apparatus; neuron projection; mitochondrion; perinuclear region of cytoplasm; endoplasmic reticulum; cytoplasm; SCF ubiquitin ligase complex; cytosol; nucleus; ubiquitin ligase complex

Molecular Function: tubulin binding; identical protein binding; ubiquitin binding; zinc ion binding; histone deacetylase binding; ubiquitin-protein ligase activity; Hsp70 protein binding; actin binding; protein kinase binding; PDZ domain binding; protein binding; G-protein-coupled receptor binding; ubiquitin conjugating enzyme binding; chaperone binding; ubiquitin protein ligase binding; heat shock protein binding; SH3 domain binding; kinase binding; ligase activity

Biological Process: protein monoubiquitination; proteasomal ubiquitin-dependent protein catabolic process; negative regulation of JNK cascade; negative regulation of actin filament bundle formation; protein polyubiquitination; startle response; central nervous system development; adult locomotory behavior; regulation of protein ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; regulation of neurotransmitter secretion; protein ubiquitination; mitochondrion localization; norepinephrine metabolic process; dopamine metabolic process; regulation of dopamine secretion; negative regulation of insulin secretion; negative regulation of glucokinase activity; zinc ion homeostasis; regulation of lipid transport; negative regulation of protein amino acid phosphorylation; dopamine uptake; negative regulation of neuron apoptosis; positive regulation of DNA binding; synaptic transmission, glutamatergic; mitochondrial fission; mitochondrion organization and biogenesis; protein autoubiquitination; positive regulation of I-kappaB kinase/NF-kappaB cascade; protein stabilization; transcription, DNA-dependent; learning; regulation of protein transport; cellular protein catabolic process; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; mitochondrion degradation; positive regulation of transcription from RNA polymerase II promoter; regulation of autophagy; response to oxidative stress

Disease: Parkinson Disease 2, Autosomal Recessive Juvenile; Leprosy, Susceptibility To, 2; Lung Cancer; Ovarian Cancer